Amy C. Moore: Meet the Expert session on cellular therapies for lung cancer at WCLC24
Amy C. Moore posted on X:
“Dr. Martin Forster and I will be leading a Meet the Expert session on cellular therapies for lung cancer at IASLC‘s WCLC24.
Come join us bright and early on Sept 8 for an interactive session to learn more about recent advances and current limitations in this space.”
Narjust Florez shared the following post adding:
“This should be a very instructive session.
WCLC24 program encapsulates the needs of all patients and the importance of team work.
Check this one out!”
Source: Amy C. Moore/X and Narjust Florez/X
Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
She received the 2020 Rising Star award by the LEAD National Conference for women in hematology and oncology. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.
Amy C. Moore, is a Ph.D.-trained virologist and cancer scientist, who has over 25 years of research experience. She is the Vice President of Global Engagement and Research Partnerships at the LUNGevity Foundation. Previously, she was the Director of Science and Research at the Addario Lung Cancer Medical Institute (ALCMI) and GO2 Foundation for Lung Cancer.
Martin Forster is a medical oncologist at the University College Hospitals, London. Dr. Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia, and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000.
He achieved a PhD at the Institute for Cancer Research, London, and was awarded the EORTC-PAMM Young Investigator Award in 2004. His areas of expertise include chemotherapy, lung and head and neck cancers, drug development, and cancer biology.